Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,605 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Dose level 2/MTD Clear all

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: Vorinostat, Pembrolizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Adenocarcinoma, Pancreatic Neoplasms
Interventions: MLN8237, nab-Paclitaxel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Myeloid Leukemia, Relapsed Adult AML
Interventions: Lintuzumab-Ac225, Venetoclax, Spironolactone; Biological · Drug
Lead sponsor: Actinium Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Louisville, Kentucky • New Orleans, Louisiana + 2 more

Conditions: Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions: NKT3447; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more

Conditions: Acute Myeloid Leukemia
Interventions: Lintuzumab-Ac-225, Cladribine, Cytarabine, Mitoxantrone, G-CSF; Biological · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Milwuakee, Wisconsin

Conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
Interventions: Treatment with CD200AR-L; Drug
Lead sponsor: OX2 Therapeutics; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnitine Palmitoyltransferase (CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency
Interventions: UX007; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 6 Months and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal
Interventions: Mithramycin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumor
Interventions: SKL27969; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Duarte, California • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more

Conditions: Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Small Intestine Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate, liposomal vincristine sulfate, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 15 more

Conditions: Glioblastoma
Interventions: Gallium maltolate (500 mg), Gallium maltolate (1,000 mg), Gallium maltolate (1,500 mg), Gallium maltolate (2,000 mg), Gallium maltolate (2,500 mg), Gallium maltolate (recommended phase 2 dose); Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Childhood CNS Primitive Neuroectodermal Tumor
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 6 Months to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Gilteritinib, Idarubicin, Cytarabine, Daunorubicin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 7 more

Conditions: Breast Cancer
Interventions: Temsirolimus, Neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 4
States / cities: Goodyear, Arizona • Los Angeles, California • New York, New York

Conditions: Brain Cancer, Glioblastoma Multiforme
Interventions: Vorinostat, Erlotinib, Temozolomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Interventions: Sotorasib, Ladarixin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Garden City, New York • Mineola, New York • New Hyde Park, New York + 1 more

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: PD-616; Drug
Lead sponsor: Biosuccess Biotech Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Duarte, California • Lexington, Kentucky

Conditions: Lymphoma
Interventions: Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B; Biological · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions: pNGVL4aCRTE6E7L2; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 19 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Dasatinib and Paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Congenital Heart Disease (CHD)
Interventions: BM-MSC; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: Up to 6 Months
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer
Interventions: Entinostat, Atezolizumab, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more

Conditions: Leukemia
Interventions: filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia
Interventions: Ruxolitinib, Cladribine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Venetoclax and Lintuzumab-Ac225 in AML Patients

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Ladarixin With Sotorasib in Advanced NSCLC

Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia